Where are We Now with US Payers on Biosimilars Pricing, Uptake and Reimbursement?

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

Mobile number:

What is your role?

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

In the presentation, he discusses biosimilars today in the US in light of BCPA / ACA reform, and future launches in the USA.

The presentation covers:

Biosimilar pathway: upsides and downsides after release of draft guidelines
The ACA Established Medicare Part B Payment for Biosimilars
Omnitrope in the USA: Serves as a critical lesson for future pharmacy benefit biosimilar launches
Patient access has the potential to be enhanced: UK Filgrastim market
Enhanced competition from the introduction of biosimilars: German EPO market all players lower list prices